[go: up one dir, main page]

AR049978A1 - Composicion farmaceutica que contiene neurotoxina botulinica - Google Patents

Composicion farmaceutica que contiene neurotoxina botulinica

Info

Publication number
AR049978A1
AR049978A1 ARP050102876A AR049978A1 AR 049978 A1 AR049978 A1 AR 049978A1 AR P050102876 A ARP050102876 A AR P050102876A AR 049978 A1 AR049978 A1 AR 049978A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
botulinic
neurotoxin
composition containing
liquid
Prior art date
Application number
Other languages
English (en)
Original Assignee
Ipsen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32865775&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR049978(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ipsen Ltd filed Critical Ipsen Ltd
Publication of AR049978A1 publication Critical patent/AR049978A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

La presente se relaciona con una compsicion farmacéutica líquida o solida que comprende complejo de neurotoxina botulínica (tipo A, B, C, D, E, F o G) o neurotoxina botulínica de alta pureza (tipo A, B, C, D, E, F o G) y un surfactante. En particular, la presente se relaciona con una composicion farmacéutica líquida o solida que comprende un agente cristalino.
ARP050102876 2004-07-12 2005-07-12 Composicion farmaceutica que contiene neurotoxina botulinica AR049978A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0415491A GB2416122A (en) 2004-07-12 2004-07-12 Botulinum neurotoxin composition

Publications (1)

Publication Number Publication Date
AR049978A1 true AR049978A1 (es) 2006-09-20

Family

ID=32865775

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP050102876 AR049978A1 (es) 2004-07-12 2005-07-12 Composicion farmaceutica que contiene neurotoxina botulinica
ARP170101893A AR108998A2 (es) 2004-07-12 2017-07-07 Composición farmacéutica que contiene neurotoxina botulínica

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP170101893A AR108998A2 (es) 2004-07-12 2017-07-07 Composición farmacéutica que contiene neurotoxina botulínica

Country Status (19)

Country Link
US (4) US9125804B2 (es)
EP (4) EP3446701B1 (es)
JP (2) JP5301830B2 (es)
CN (2) CN102327602B (es)
AR (2) AR049978A1 (es)
BR (1) BRPI0513327B8 (es)
CA (1) CA2572915C (es)
DK (3) DK1817051T4 (es)
ES (3) ES2438780T5 (es)
FI (1) FI1817051T4 (es)
GB (1) GB2416122A (es)
HU (2) HUE043301T2 (es)
IL (1) IL180380A (es)
MX (1) MX2007000409A (es)
PL (3) PL1817051T5 (es)
PT (3) PT1817051E (es)
RU (1) RU2407541C2 (es)
TR (1) TR201906275T4 (es)
WO (1) WO2006005910A2 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763663B2 (en) 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
CN101083907B (zh) 2004-03-03 2012-10-10 雷文斯治疗公司 用于局部诊断剂和治疗剂运输的组合物和方法
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
US9180081B2 (en) 2005-03-03 2015-11-10 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
WO2008010788A2 (en) 2005-07-18 2008-01-24 University Of Massachusetts Lowell Compositions and methods for making and using nanoemulsions
FR2889936B1 (fr) 2005-09-01 2007-12-21 Sod Conseils Rech Applic Methode pour quantifier une neurotoxine cholinergique dans un echantillon
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
AU2016204034B2 (en) * 2005-10-06 2017-12-21 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
PT1959994T (pt) 2005-12-01 2017-11-30 Univ Massachusetts Lowell Nanoemulsões botulínicas
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
FR2902341B1 (fr) 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
MX2009005727A (es) 2006-12-01 2009-08-27 Anterios Inc Nanoparticulas de entidad anfifilica.
WO2008140594A2 (en) * 2006-12-01 2008-11-20 Anterios, Inc. Peptide nanoparticles and uses therefor
FR2910327B1 (fr) 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
EP2162117B1 (en) 2007-05-31 2018-02-21 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
KR101087017B1 (ko) 2007-07-10 2011-12-09 (주)메디톡스 보툴리눔 독소의 안정성이 개선된 약제학적 액상 조성물
FR2930447B1 (fr) 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
EP3650017A1 (en) * 2008-06-26 2020-05-13 Anterios, Inc. Dermal delivery
ES2356883B1 (es) * 2008-07-24 2012-02-22 Bcn Peptides, S.A. Composición para el tratamiento del dolor y/o la inflamación.
CN101386648B (zh) * 2008-09-25 2012-05-30 中国人民解放军军事医学科学院微生物流行病研究所 抗b型肉毒神经毒素中和性单克隆抗体、其制备方法及用途
EP3067049A1 (en) * 2008-12-10 2016-09-14 Allergan, Inc. Clostridial toxin pharmaceutical compositions
AU2009332947C1 (en) 2008-12-31 2019-01-03 Revance Therapeutics, Inc. Injectable botulinum toxin formulations
EP2248518B1 (en) 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
KR101975051B1 (ko) * 2009-06-25 2019-05-03 레반스 테라퓨틱스, 아이엔씨. 알부민­불포함 보툴리눔 독소 제제
AU2011316111B2 (en) 2010-10-12 2015-05-28 Merz Pharma Gmbh & Co. Kgaa Formulation suitable for stabilizing proteins, which is free of mammalian excipients
CN103596580A (zh) * 2011-03-31 2014-02-19 株式会社美得拓石 肉毒杆菌毒素冻干制剂
US9498521B2 (en) * 2011-09-28 2016-11-22 Wisconsin Alumni Research Foundation Purification, characterization, and use of Clostridium botulinum neurotoxin BoNT/A3
GB201219602D0 (en) * 2012-10-31 2012-12-12 Syntaxin Ltd Recombinant clostridium botulinum neurotoxins
JP2015534814A (ja) * 2012-10-31 2015-12-07 イプセン バイオイノベーション リミテッド 組換えクロストリジウムボツリヌス神経毒
MX377653B (es) 2013-03-15 2025-03-11 Orpro Therapeutics Inc Producto y uso para normalización de la viscoelasticidad del moco.
RU2535115C1 (ru) * 2013-05-15 2014-12-10 Бости Трейдинг Лтд Фармацевтический состав, содержащий нейротоксин ботулина
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
RU2593344C2 (ru) * 2014-03-05 2016-08-10 Михаил Григорьевич Сойхер Способ лечения бруксизма
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
EP3236939B2 (en) 2014-12-23 2024-08-28 Merz Pharma GmbH & Co. KGaA Botulinum toxin prefilled container
JP6813492B2 (ja) 2015-02-03 2021-01-13 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン ボツリヌス毒素充填済み容器
SG10202004337WA (en) 2015-10-29 2020-06-29 Revance Therapeutics Inc Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect
US10874626B2 (en) 2016-04-07 2020-12-29 Nevakar Inc. Formulation for use in a method of treatment of pain
HRP20202070T1 (hr) 2016-05-27 2021-02-19 Ipsen Biopharm Limited Tekuća neurotoksinska formulacija stabilizirana s triptofanom ili tirozinom
RU2651044C2 (ru) * 2016-08-22 2018-04-18 федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр имени академика Е.Н. Мешалкина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ им. ак. Е.Н. Мешалкина" Минздрава России) Способ лечения желудочковых нарушений ритма сердца (варианты)
WO2018038301A1 (en) * 2016-08-26 2018-03-01 Hugel Inc. Stabilized liquid formulation of botulinum toxin and preparation method thereof
JP2019526611A (ja) 2016-09-13 2019-09-19 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 非タンパク質クロストリジウム毒素組成物
BR112019010131A2 (pt) 2016-11-21 2019-10-08 Eirion Therapeutics, Inc. entrega transdérmica de agentes grandes
KR101744900B1 (ko) 2017-01-20 2017-06-08 주식회사 대웅 보툴리눔 독소를 포함하는 안정한 액상 조성물
SI3583125T1 (sl) 2017-02-16 2025-06-30 Sonnet BioTherapeutics, Inc. Fuzijski proteini z albumin-vezavno domeno
CN111432882A (zh) 2017-10-03 2020-07-17 内瓦卡公司 对乙酰氨基酚-普瑞巴林组合和治疗疼痛的方法
US10918586B2 (en) * 2017-12-07 2021-02-16 Ps Therapy Ltd. Topical compositions and methods of use thereof
AU2020226945B2 (en) 2019-02-21 2025-12-04 Merz Pharma Gmbh & Co. Kgaa Novel uses of botulinum neurotoxin for the treatment of tremor
RU2728102C1 (ru) * 2019-12-19 2020-07-28 Александр Александрович Ильин Способ лечения гипертонуса латеральной крыловидной мышцы
KR102324855B1 (ko) * 2020-05-20 2021-11-11 오스템임플란트 주식회사 보툴리눔 독소를 포함하는 약제학적 액상 조성물
WO2022131860A1 (ko) * 2020-12-18 2022-06-23 주식회사 에이티지씨 보툴리눔 독소의 액상 제제를 장기 보관하기 위한 약제학적 조성물
CN119258202A (zh) * 2023-07-05 2025-01-07 重庆誉颜制药有限公司 一种肉毒毒素蛋白组合物及其应用
US12134635B1 (en) 2023-12-29 2024-11-05 Sonnet BioTherapeutics, Inc. Interleukin 18 (IL-18) variants and fusion proteins comprising same

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457916A (en) 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
JP3905921B2 (ja) 1992-10-02 2007-04-18 ジェネティクス インスチチュート リミテッド ライアビリティー カンパニー 凝固第▲ｖｉｉｉ▼因子を含む組成物及びその製造方法並びに安定剤としての界面活性剤の使用方法
US5756468A (en) * 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
US5512547A (en) 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US20030095927A1 (en) 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
WO1999037326A1 (en) 1998-01-26 1999-07-29 University Of Massachusetts Biologically active hemagglutinin from type a clostridium botulinum and methods of use
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
IL149778A0 (en) 1999-11-22 2002-11-10 Universal Preservation Technologies Inc Preservation of sensitive biological material
NZ520201A (en) † 2000-02-08 2004-04-30 Allergan Inc Botulinum toxin pharmaceutical compositions comprising a polysaccharide
US20030118598A1 (en) † 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US7255865B2 (en) 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
AU2002320127A1 (en) 2001-06-21 2003-01-08 Surromed, Inc. Covalent coupling of botulinum toxin with polyethylene glycol
WO2003101483A1 (en) * 2002-05-31 2003-12-11 Solux Corporation Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
RU2206337C1 (ru) 2002-10-29 2003-06-20 Общество с ограниченной ответственностью "Токсины и сопутствующие продукты" Лекарственный препарат для лечения мышечных дистоний и способ его получения
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
GB2416122A (en) * 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
EP2813239B1 (en) 2004-08-04 2017-03-22 Ipsen Biopharm Limited Pharmaceutical composition containing botulinum neurotoxin A2
EP1778279B1 (en) * 2004-08-04 2014-12-03 Ipsen Biopharm Limited Pharmaceutical composition containing botulinum neurotoxin a2
US8137677B2 (en) 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions

Also Published As

Publication number Publication date
HUE025434T2 (en) 2016-05-30
US10561604B2 (en) 2020-02-18
FI1817051T4 (fi) 2024-05-02
ES2725908T3 (es) 2019-09-30
HK1152863A1 (en) 2012-03-16
IL180380A (en) 2015-11-30
US9757329B2 (en) 2017-09-12
US11534394B2 (en) 2022-12-27
HUE043301T2 (hu) 2019-08-28
DK2269631T3 (da) 2013-12-09
EP2269631A3 (en) 2012-04-11
US20080050352A1 (en) 2008-02-28
CN1984675A (zh) 2007-06-20
US20170348226A1 (en) 2017-12-07
CN1984675B (zh) 2011-11-09
EP1817051B1 (en) 2015-02-25
EP1817051A2 (en) 2007-08-15
EP3446701B1 (en) 2025-11-19
WO2006005910A3 (en) 2006-09-14
CN102327602B (zh) 2017-07-07
EP2939688A1 (en) 2015-11-04
EP2939688B1 (en) 2019-02-20
US9125804B2 (en) 2015-09-08
DK1817051T4 (da) 2024-05-06
DK1817051T3 (en) 2015-06-01
PL1817051T3 (pl) 2015-07-31
IL180380A0 (en) 2007-06-03
PT2269631E (pt) 2014-01-08
EP2269631B1 (en) 2013-10-09
GB0415491D0 (en) 2004-08-11
JP5662379B2 (ja) 2015-01-28
BRPI0513327B8 (pt) 2021-05-25
ES2537312T3 (es) 2015-06-05
WO2006005910A2 (en) 2006-01-19
PL2269631T3 (pl) 2014-02-28
HK1102495A1 (en) 2007-11-23
RU2407541C2 (ru) 2010-12-27
CA2572915C (en) 2015-01-20
PL2269631T5 (pl) 2020-08-10
DK2939688T3 (da) 2019-05-13
ES2438780T3 (es) 2014-01-20
GB2416122A (en) 2006-01-18
EP2269631A2 (en) 2011-01-05
JP2012211150A (ja) 2012-11-01
ES2438780T5 (es) 2019-12-23
EP1817051B2 (en) 2024-04-10
ES2537312T5 (es) 2024-09-18
US20200164050A1 (en) 2020-05-28
JP5301830B2 (ja) 2013-09-25
CA2572915A1 (en) 2006-01-19
JP2008505961A (ja) 2008-02-28
EP3446701A1 (en) 2019-02-27
BRPI0513327B1 (pt) 2020-09-29
US20150328293A1 (en) 2015-11-19
TR201906275T4 (tr) 2019-05-21
EP2269631B2 (en) 2019-06-12
AR108998A2 (es) 2018-10-17
PT2939688T (pt) 2019-05-28
BRPI0513327A (pt) 2008-05-06
DK2269631T4 (da) 2019-08-19
PL2939688T3 (pl) 2019-12-31
RU2007101307A (ru) 2008-08-20
MX2007000409A (es) 2007-06-25
PL1817051T5 (pl) 2024-07-29
CN102327602A (zh) 2012-01-25
PT1817051E (pt) 2015-06-03

Similar Documents

Publication Publication Date Title
AR049978A1 (es) Composicion farmaceutica que contiene neurotoxina botulinica
AR055444A1 (es) Uso y produccion de metalopretasa neutra estable al almacenamiento
PE20090605A1 (es) Composiciones de fenilalanina amoniaco-liasa procariotica y metodos del tratamiento del cancer usando composiciones de la misma
ES2580635T3 (es) Composición cosmética que comprende un agente estructurante, un agente absorbente y un agente tensioactivo para la aplicación a las materias queratínicas
SE0201980D0 (sv) Novel compounds
MX2008011085A (es) Composiciones antimicrobianas y metodos para sellar cateteres.
PA8564101A1 (es) Composiciones de goma de mascar y confiteria con composiciones de agente que elimina manchas encapsulado y procedimientos para su fabricacion y uso
DK1475101T3 (da) Antistof-holdige farmaceutiske opløsninger
MX2009011566A (es) Uso de hidrolizados de proteinas para estabilizar formulaciones detergentes que contienen metaloproteasa.
AR052069A1 (es) Composiciones detergentes liquidas substancialmente no acuosas y su utilizacion
AR040093A1 (es) Composicion limpiadora que comprende perlas suspendidas
AR022889A1 (es) Agente desfoliante
AR043906A1 (es) Composiciones limpiadoras para superficies duras
MXPA05012319A (es) Suministro de compuestos con celulas sanguineas rehidratadas.
AR058035A1 (es) Formulacion de micro-emulsion
AR058605A1 (es) Preparacion solida
CY1112820T1 (el) Φαρμακοτεχνικες μορφες της ρεg-ιντερφερονης-βητα
SE0201977D0 (sv) Novel compounds
BRPI0618654A8 (pt) variante de zimogênio/protease de fator x/fator xa, ácido nucléico, composição farmacêutica que os contém, vetor, bem como uso dos mesmos
AR061247A1 (es) Enzima dmo modificada y metodos de uso de la misma
SE0203712D0 (sv) Novel compounds
AR030648A1 (es) Composicion farmaceutica con excipiente modificado
AR030647A1 (es) Composicion farmaceutica con actividad de agua especifica
AR061274A1 (es) Composicion liquida de limpieza para superficies duras
UA93540C2 (ru) Фармацевтическая композиция для аэрозольного распыления c двумя действующими веществами и, по меньшей mepe, одним поверхностно-активным веществом

Legal Events

Date Code Title Description
FC Refusal